Are you in the process of listing or are you thinking of listing? This New Kids on the Stock BioBriefing will profile recently listed companies and speakers will share their top-tips and the lessons learned from their experience of listing on the Australian Stock Exchange. James Gerraty, Listings Manager from the Australian Stock Exchange will also discuss the process of listing and secondary capital raising.
This will be an interactive session and questions can be put to the panel to promote discussions around what happened that was expected and unexpected? How they overcame challenges? What their next steps will be and what benefits have they seen so far?
At this event our panel will be providing an overview of their process and then taking part in a discussion which will cover considerations such as IP position, company structure, legal due diligence, timelines and internal versus external expertise.
Date: Tuesday 28th February, 2017
Time: 4:00pm – 5:30pm followed by a networking session
Venue: KPMG, Tower 2, 727 Collins Street, Melbourne VIC 3000 Australia
(Prices include GST)
To check if your organisation is a member, click here
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
James Gerraty has been ASX’s Manager of Listings in Melbourne since 2000. ASX is one of the world’s top 10 listed stock exchange groups. The Listings unit of ASX is concerned with ensuring ASX provides fair, orderly and transparent markets.
As well as managing the relationships ASX has with Victorian based entities listed on the exchange, James and his team facilitate new listings and secondary capital raisings on the market. James is a member and Deputy Chairman of the ASX Listing Committee.
Kathy has more than 20 years experience within the Australian Biotech Industry.
Previously, Kathy has worked within ASX listed companies AMRAD Biotech, Cytopia Research Pty Ltd, and Phosphagenics Limited, in a wide variety of functions including product development, clinical development, and IP strategy and management.
Kathy also spent 9 years in private practice as a patent and trade mark attorney, gaining a wealth of experience in the legal framework underscoring commercialisation of technologies.
Kathy holds a Master of Science from Manchester University (UK), a Certificate in Governance (Practice) from the Governance Institute of Australia, and is a Registered Patent and Trade Mark Attorney in Australia and Fellow of the Institute of Patent and Trade Mark Attorneys.
Prue Kelly, Investor Relations Manager, Noxopharm
Earlier careers in teaching, teaching administration and merchant banking have equipped Prue well for her current role as Investor Relations Manager at Noxopharm Limited.
After graduating with a degree in Education from the University of Sydney, Prue taught and later took the position of Principal, at schools in both Sydney and London. After returning to Australia, she worked at The Australian Bank and then at Bankers Trust Australia in a Treasury role.
Prue worked at Novogen from 2012 in an investor communications capacity, and after leaving there in mid-2015, was implicit in the formation, and Australian Securities Exchange listing of Noxopharm Limited in August 2016.
In 2016, Simon led the team assisting AdAlta with its successful IPO on the ASX, raising $10million in an oversubscribed IPO.
Simon has over 20 years’ experience across the spectrum of corporate transactions, especially in equity capital markets and mergers & acquisitions, as well general corporate advisory. He has worked at Minter Ellison, Eversheds and was most recently a partner at DLA Piper before establishing Hive Legal. Simon has been noted in Legal 500 in five editions (including the recently published 2017 edition) for capital markets and M&A.